Outlook Therapeutics, Inc.
- Open
- 0.63
- Day high
- 0.66
- Day low
- 0.63
- Prev close
- 0.64
- Volume
- 6.4M
- Mkt cap
- $154M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -14.8
- P/S
- -132.6
- Yield
- —
- Per share
- —
- ▲Insiders net buying $2.9M over the last 3 months (5 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions reducing (13F)
Outlook Therapeutics, Inc. (OTLK) is a Healthcare company listed on NASDAQ. The stock is down 26% over the past year. Over the trailing 3 months, insiders filed 5 open-market buys and 0 sales (SEC Form 4).
Outlook Therapeutics, Inc. (OTLK) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
OTLK earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 14, 2026 | $-0.08 | $-0.14 | -75.0% | — | — |
| May 15, 2026 | $-0.12 | $-0.16 | -33.3% | $128000 | -97.1% |
| Feb 17, 2026 | $-0.17 | $-0.22 | -29.4% | $-1M | -149.0% |
| Dec 19, 2025 | $-0.23 | $-0.22 | +4.3% | $-91787 | -101.6% |
| Aug 14, 2025 | $-0.42 | $-0.44 | -4.8% | $2M | -74.3% |
| May 15, 2025 | $-0.55 | $-0.40 | +27.3% | — | — |
| Feb 14, 2025 | $-0.85 | $-0.89 | -4.7% | — | — |
| Dec 27, 2024 | $-0.83 | $-0.77 | +7.2% | — | — |
| Aug 14, 2024 | $-1.06 | $-0.83 | +21.7% | — | — |
| May 15, 2024 | $-0.88 | $-1.55 | -76.1% | — | — |
| Feb 14, 2024 | $-1.00 | $-0.80 | +20.0% | — | — |
| Dec 22, 2023 | $-1.00 | $-1.00 | +0.0% | — | — |
OTLK insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Sukhtian Ghiath M.director, 10 percent owner: | Buy | 2,525,252 | $0.99 |
| Aug 14, 2026 | Jahr Robert Charlesdirector, officer: Chief Executive Officer | Buy | 151,515 | $0.99 |
| Aug 14, 2026 | KENYON LAWRENCE Adirector, officer: Chief Financial Officer | Buy | 101,010 | $0.99 |
| Jul 29, 2026 | Sukhtian Faisal Ghiathdirector | Buy | 95,398 | $1.05 |
| Jul 23, 2026 | KENYON LAWRENCE Adirector, officer: Chief Financial Officer | Grant | 210,078 | $1.43 |
| Jul 23, 2026 | Jahr Robert Charlesdirector, officer: Chief Executive Officer | Grant | 100,000 | $1.43 |
| Jun 3, 2026 | Haddadin Yezan Muntherdirector | Buy | 29,000 | $0.83 |
| Jun 1, 2026 | Sukhtian Ghiath M.director, 10 percent owner: | Buy | 8,539,709 | $0.59 |
| Jun 1, 2026 | Sukhtian Ghiath M.director, 10 percent owner: | Buy | 3,458,571 | $0.59 |
| Jun 1, 2026 | Sukhtian Ghiath M.director, 10 percent owner: | Buy | 8,571,428 | $0.59 |
| May 27, 2026 | Sukhtian Faisal Ghiathdirector | Buy | 122,174 | $0.41 |
| May 27, 2026 | Haddadin Yezan Muntherdirector | Buy | 34,000 | $0.44 |
| May 27, 2026 | HILZINGER KURT Jdirector | Buy | 400,000 | $0.44 |
| May 27, 2026 | THURMAN RANDY Hdirector | Buy | 5,000 | $0.43 |
| Oct 3, 2025 | Haller Julia Adirector | Grant | 58,648 | $1.06 |
Source: OTLK SEC Form 4 filings, latest Aug 14, 2026. For informational purposes only — not investment advice.
See the full OTLK insider & 13F page →Outlook Therapeutics, Inc. company profile
Overview
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a late-stage biopharmaceutical company founded in 2010 and headquartered in Iselin, New Jersey. Originally incorporated as Oncobiologics, Inc., the company rebranded to Outlook Therapeutics in November 2018 to reflect its strategic pivot toward ophthalmology. The company went public in 2016 and has evolved from a broader oncology focus to specialize exclusively in developing monoclonal antibody treatments for eye diseases, particularly retinal disorders that can cause blindness.
Business
Outlook Therapeutics operates in the specialized field of ophthalmic biologics, developing treatments for serious eye diseases that affect the retina - the light-sensitive tissue at the back of the eye. The company's entire focus centers on ONS-5010, which is an ophthalmic (eye-specific) formulation of bevacizumab, a well-known cancer drug that has been repurposed for eye treatments. To understand the significance of this product, it's important to know that wet age-related macular degeneration (wet AMD) is a leading cause of blindness in people over 50. This condition occurs when abnormal blood vessels grow under the retina and leak fluid, causing vision loss. Current treatments involve injecting anti-VEGF (vascular endothelial growth factor) drugs directly into the eye to stop this abnormal blood vessel growth. Currently, doctors often use bevacizumab "off-label" for eye treatments, meaning they use a cancer drug that wasn't specifically approved or formulated for eye use. ONS-5010 represents the first bevacizumab product specifically designed, tested, and manufactured for injection into the eye. The company is also developing ONS-5010 for other retinal diseases including diabetic macular edema (swelling in diabetics' eyes) and branch retinal vein occlusion (blocked blood vessels in the retina). The company operates as a single business segment focused entirely on this ophthalmic franchise, with no current revenue as it remains in the clinical development phase.
Revenue model
Outlook Therapeutics follows a typical biotech business model where the company will generate revenue through product sales once ONS-5010 receives regulatory approval and launches commercially. The paying customers will be healthcare systems, hospitals, and specialty eye clinics that treat patients with retinal diseases. The company plans to sell directly in some markets while partnering with distributors in others. The revenue model depends on successful navigation of regulatory approvals. In Europe, the company has already received marketing authorization and plans to launch in the first half of 2025, starting with Germany and the UK. For the US market, the company must complete its ongoing Phase III clinical trial (NORSE EIGHT) and resubmit its application to the FDA, targeting a Q1 2025 resubmission. Several factors could significantly impact the company's margins and success. Positive factors include the large and growing market for retinal disease treatments, driven by aging populations, and the potential cost advantages of ONS-5010 compared to existing branded competitors like Lucentis and Eylea. The company's product could offer similar efficacy at a lower price point. Negative factors include intense competition from established players, the risk of regulatory setbacks, manufacturing complexities associated with biologics production, and the challenge of gaining physician adoption in a market where off-label bevacizumab use is already common. Additionally, healthcare reimbursement decisions and pricing pressures from payers could significantly impact profitability.
Competitive moat
Outlook Therapeutics faces significant moat challenges in a highly competitive ophthalmic market. The company's primary competitive advantage lies in being the first purpose-built bevacizumab formulation specifically designed for ophthalmic use, which could provide quality, safety, and regulatory advantages over off-label bevacizumab use. However, this moat is relatively narrow. The company competes against well-established players including Regeneron's Eylea, Roche/Genentech's Lucentis, and widespread off-label use of Avastin (bevacizumab). These competitors have significant advantages including established market presence, extensive clinical data, strong physician relationships, and substantial financial resources for marketing and development. The regulatory approval in Europe provides some temporary competitive positioning, but this advantage is limited by the relatively small barriers to entry for other biosimilar developers. Large pharmaceutical companies with deeper resources could potentially develop competing bevacizumab formulations or advance next-generation treatments. The company's patent protection and regulatory exclusivity periods will be crucial for maintaining any competitive advantage. Overall, Outlook Therapeutics operates in a market with limited sustainable moats, where success depends heavily on execution, pricing strategy, and the ability to demonstrate clear clinical and economic advantages over existing alternatives. The company's position is vulnerable to both established competitors and potential new entrants with superior resources or technology.
Risks & safety
The margin of safety appears concerning for this pre-revenue biotech company facing significant cash burn and execution risks. • Cash burn and solvency: With approximately $15 million in cash as of Q4 2024 and quarterly operating cash outflows of $17-20 million, the company faces near-term liquidity constraints. Management expects additional funding from warrant exercises ($107 million potential) but this depends on stock price performance and warrant holder decisions. • Debt and liabilities: Total liabilities of $102 million significantly exceed assets of $29 million, creating a negative book value situation. Current ratio of 0.64 indicates potential short-term liquidity issues. • Valuation metrics: With no revenue and inconsistent profitability, traditional valuation metrics are not meaningful. The $81 million market cap represents a speculative bet on regulatory and commercial success. • Other considerations: Binary risk profile where success depends entirely on FDA approval and successful commercial launch. Limited diversification with single product candidate creates concentration risk.
Recent development
Over the past few years, Outlook Therapeutics has made significant strategic progress toward commercialization. The most notable achievement was receiving marketing authorization in the European Union and United Kingdom, positioning the company for its first commercial launch in the first half of 2025, initially targeting Germany and the UK markets. In the United States, the company has been executing its NORSE EIGHT Phase III clinical trial, which enrolled 359 of 400 planned patients as of the last update. This trial is critical for the company's planned resubmission of its Biologics License Application (BLA) to the FDA in Q1 2025, following previous regulatory feedback. The company has completed Type C and Type D meetings with the FDA to address chemistry, manufacturing, and controls (CMC) questions from their previous submission. On the operational front, the company has established key partnerships including working with Cencora (formerly AmerisourceBergen) for European distribution infrastructure. The company has also been preparing for commercial launch through market access initiatives, health technology assessments, and building sales and medical scientific liaison teams. Additionally, Outlook has been exploring partnership opportunities and has existing collaboration agreements with several international partners including IPCA Laboratories, Laboratorios Liomont, BioLexis, and Zhejiang Huahai Pharmaceutical for various geographic markets.
OTLK company profile · for informational purposes only — not investment advice.
Track OTLK with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free